Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • 10 hours ago

Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Again

Pharvaris stock jumped early Monday after the FDA agreed to review the company's experimental treatment for a serious swelling disease.

Investors Business Daily • Jul 6, 2026

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.

GlobeNewsWire • Jul 6, 2026

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, which took place from June 12-15, 2026, in Istanbul, Turkey.

GlobeNewsWire • Jun 15, 2026

Pharvaris Announces Annual General Meeting of Shareholders

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

GlobeNewsWire • Jun 11, 2026

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey.

GlobeNewsWire • May 29, 2026

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Cash and cash equivalents of €247 million as of March 31, 2026; subsequent closing of $132 million underwritten offering extends cash runway into 2028 ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the first quarter ended in March 31, 2026, and provided a business update. “In 2026, Pharvaris remains focused on execution across our late-stage programs, including reporting CHAPTER-3 data in the third quarter and enrolling in CREAATE, and on establishing our commercial infrastructure in preparation for the potential launch of deucrictibant IR,” said Berndt Modig, Chief Executive Officer of Pharvaris.

GlobeNewsWire • May 12, 2026

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (“HAE”) and acquired angioedema due to C1 inhibitor deficiency (“AAE-C1INH”), today announced the closing of its previously announced underwritten offering of 4,455,863 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 581,199 ordinary shares). The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $132.3 million. All shares in the offering were sold by Pharvaris.

GlobeNewsWire • May 11, 2026

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (“HAE”) and acquired angioedema due to C1 inhibitor deficiency (“AAE-C1INH”), announced today the pricing of an underwritten offering of 3,874,664 of its ordinary shares at a price of $29.68 per share. All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $115 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 11, 2026, subject to satisfaction of customary closing conditions.

GlobeNewsWire • May 8, 2026